-
Biohaven to present additional Phase 3 Rimegepant Data at AAN 2018
- April 20, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
Alder to present Phase 3 Eptinezumab results at AAN 2018
- April 20, 2018
- Posted by: PharmaScroll
- Category:
-
Novel Multiple Sclerosis Biomarker to measure severity of disease, suggests study
- April 20, 2018
- Posted by: PharmaScroll
- Category:
-
First Phase I candidate recruited for Jülich’s Alzheimer’s therapy
- April 19, 2018
- Posted by: PharmaScroll
- Category:
-
Biogen’s BIIB054 displays positive Phase I results in Parkinson’s
- April 19, 2018
- Posted by: PharmaScroll
- Category:
-
Teva to Present New Data Across Multiple NS Therapeutic Areas at AAN
- April 18, 2018
- Posted by: PharmaScroll
- Category:
-
National MS Society commits $14.2 Million to new MS research
- April 18, 2018
- Posted by: PharmaScroll
- Category:
-
Aimovig halves Migraine days in difficult to treat patients, study to be presented an AAN finds
- April 18, 2018
- Posted by: PharmaScroll
- Category:
-
GW cannabis-derived epilepsy drug gets positive FDA staff review
- April 17, 2018
- Posted by: PharmaScroll
- Category:
-
SPMS patients have higher cognitive decline than RRMS patients, study reports
- April 17, 2018
- Posted by: PharmaScroll
- Category: